Trebananib, the experimental last stage platinum-resistant ovarian cancer drug by Amgen, fails to improve overall survival (OS) rate very significantly, it was revealed earlier today. Patient on whom this new drug was tried out, along with a chemotherapy agent paclitaxel, were found to live only a month longer than those who were administered only a placebo. The survival period for people put on this drug was a very slightly higher 19.3 months, as against a period of 18.3 months for those who were not put on it.
These new data follow a successful hit on the goal for progression-free survival. Amgen was expecting much better results from this experimental drug. The drug has been hotly discussed among analysts ad the investors of the company.